Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Geographic Atrophy of the Macula Clear all
Completed Not applicable Interventional

Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)

NCT05447650
View directory record Official record
Conditions
Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration
Interventions
i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham
Device
Lead sponsor
i-Lumen Scientific, Inc.
Industry
Eligibility
50 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Walnut Creek, California • Lemont, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 17, 2026, 5:46 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

NCT06659549
View directory record Official record
Conditions
Geographic Atrophy of the Macula
Interventions
GAL-101, Placebo
Drug
Lead sponsor
Galimedix Therapeutics Inc
Industry
Eligibility
55 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 17, 2026, 5:46 AM EDT
Completed Phase 2 Interventional

Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration

NCT00940407
View directory record Official record
Conditions
Nonexudative Age-related Macular Degeneration
Interventions
Photobiomodulation (Gentlewaves, Warp 10)
Device
Lead sponsor
Merry, Graham, M.D.
Individual
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Oak Ridge, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Sep 17, 2026, 5:46 AM EDT
Completed Not applicable Interventional Results available

The Zeaxanthin and Visual Function Study

NCT00564902
View directory record Official record
Conditions
Age Related Macular Degeneration, Cognition Disorders
Interventions
3R 3'R Zeaxanthin, Lutein, Lutein and Zeaxanthin
Drug · Dietary Supplement
Lead sponsor
Chrysantis, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Sep 17, 2026, 5:46 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

GARM II: A Study on the Genetics of Age-related Maculopathy

NCT01115387
View directory record Official record
Conditions
Age-related Macular Degeneration, Age-related Maculopathy
Interventions
Observational-1, Observational-2
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
49 Years and older
Enrollment
603 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 17, 2026, 5:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO

NCT01692938
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Central Serous Retinopathy, Pattern Dystrophy of Macula, Epiretinal Membrane, Macular Hole
Interventions
Not listed
Lead sponsor
Optos, PLC
Industry
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Baltimore, Maryland • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 17, 2026, 5:46 AM EDT
Active, not recruiting Phase 2 Interventional

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

NCT05230537
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Iptacopan (LNP023), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
22
States / cities
Fullerton, California • Huntington Beach, California • Rancho Cordova, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 17, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration

NCT00447954
View directory record Official record
Conditions
Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
Interventions
High Dose NT-501 implant, Low Dose NT-501 implant, Sham
Combination Product · Other
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Beverly Hills, California • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 17, 2026, 5:46 AM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration

NCT01601483
View directory record Official record
Conditions
Nonexudative Age Related Macular Degeneration
Interventions
MC-1101, MC-1101 Vehicle
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 27, 2014 · Synced Sep 17, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

NCT01922128
View directory record Official record
Conditions
Nonexudative Age-related Macular Degeneration
Interventions
MC-1101, Placebo
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 17, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

NCT04005352
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 17, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

NCT04597632
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 17, 2026, 5:46 AM EDT
Completed Phase 2 Interventional

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NCT05839041
View directory record Official record
Conditions
Geographic Atrophy of the Macula, Macular Degeneration
Interventions
AVD-104, Avacincaptad
Drug
Lead sponsor
Aviceda Therapeutics, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
56
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 17, 2026, 5:46 AM EDT
Recruiting Not applicable Interventional

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

NCT06662162
View directory record Official record
Conditions
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
i-Lumen AMD
Device
Lead sponsor
i-Lumen Scientific AUS PTY LTD
Industry
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Poway, California • Manchester, Connecticut • Lemont, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 5:46 AM EDT